Bristol Myers Squibb selected Houston for a new $2.3 billion multi-modal manufacturing campus to produce drug product and finished goods from late development through commercial launch. The plan expands BMS’s capacity footprint as it scales platform assets and supports multiple programs across modalities. At the same time, Recursion and Roche—including Genentech—announced plans to co-develop a neuroscience discovery program based on a validated target identified through an AI map. The partnership links discovery outputs from machine-learning target finding to program-level development. The package of updates highlights BMS’s dual focus: ramping manufacturing depth while pairing AI-discovery collaborations to build future pipeline entries, particularly in disease areas where target validation is a gating step.